Filing Flows › Veracyte (VCYT) › Q3 2025
Veracyte (VCYT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Veracyte (VCYT) reported revenue of $132M for the third quarter 2025 (Q3 2025), +14% from a year earlier and +1% from the quarter before. Operating margin was 17.4%, net earnings $19.1M (14.5% of revenue).
Veracyte, Q3 2025: revenue $132M (+14% year over year), operating margin 17.4%, net earnings $19.1M, operating cash flow $44.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $132M | +1% | +14% |
| Gross profit | $91.3M | +2% | +16% |
| Operating profit | $22.9M | — | +91% |
| Net earnings | $19.1M | — | +26% |
| Operating cash flow | $44.8M | +33% | +49% |
| Free cash flow | $42.0M | +30% | +51% |
What changed
Revenue was $131.9M in Q3 2025, up 14% year over year and up 1% from the previous quarter. Testing revenue was the largest line at 97% of revenue. Testing revenue added $18.2M year over year (up 17%), 114% of the total change. Contract manufacturing and testing declined 85%.
Gross margin was 69.2%, up 1.0 points from a year earlier. Operating profit was $22.9M, a 17.4% margin (up 7.0 points year over year). Of the extra revenue versus a year earlier, 68% reached operating profit, above the 10% margin then. Operating expenses grew 2% against revenue growth of 14%. Net earnings were $19.1M, up 26% year over year. The effective tax rate was -1.3%.
Operating cash flow was $44.8M (up 49% year over year), 234% of net earnings. Non-cash charges added back $5.3M of depreciation and amortization and $10.8M of share-based compensation. Working capital and other items added $9.6M. Capital expenditures of $2.8M left free cash flow of $42.0M.
Questions
What was Veracyte's revenue in the third quarter 2025?
Veracyte (VCYT) reported revenue of $132M for the third quarter 2025 (Q3 2025), +14% from a year earlier and +1% from the quarter before.
Was Veracyte profitable in the third quarter 2025?
Operating profit was $22.9M (17.4% of revenue) and net earnings $19.1M.
Source: Veracyte 10-Q on SEC EDGAR.